JP2004520337A - フィルム形成治療化合物および治療システム - Google Patents
フィルム形成治療化合物および治療システム Download PDFInfo
- Publication number
- JP2004520337A JP2004520337A JP2002555760A JP2002555760A JP2004520337A JP 2004520337 A JP2004520337 A JP 2004520337A JP 2002555760 A JP2002555760 A JP 2002555760A JP 2002555760 A JP2002555760 A JP 2002555760A JP 2004520337 A JP2004520337 A JP 2004520337A
- Authority
- JP
- Japan
- Prior art keywords
- film
- therapeutic
- compound
- forming
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 91
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 68
- 239000000126 substance Substances 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000004014 plasticizer Substances 0.000 claims abstract description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004202 carbamide Substances 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 57
- 238000010438 heat treatment Methods 0.000 claims description 28
- -1 chemotherapeutics Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 229960003338 crotamiton Drugs 0.000 claims description 8
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 7
- 239000000739 antihistaminic agent Substances 0.000 claims description 7
- 239000003096 antiparasitic agent Substances 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229920002725 thermoplastic elastomer Polymers 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 6
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000020 Nitrocellulose Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 230000002141 anti-parasite Effects 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 229940125687 antiparasitic agent Drugs 0.000 claims description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 239000002254 cytotoxic agent Substances 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical group CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 239000001087 glyceryl triacetate Substances 0.000 claims description 6
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 229920001220 nitrocellulos Polymers 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 229960002622 triacetin Drugs 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 229940125715 antihistaminic agent Drugs 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 5
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 229940049964 oleate Drugs 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 5
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 5
- 239000011118 polyvinyl acetate Substances 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
- 229930182566 Gentamicin Natural products 0.000 claims description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 125000005396 acrylic acid ester group Chemical group 0.000 claims description 4
- 229940035674 anesthetics Drugs 0.000 claims description 4
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 4
- 229940121357 antivirals Drugs 0.000 claims description 4
- 229960002537 betamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
- 229960000846 camphor Drugs 0.000 claims description 4
- 229930008380 camphor Natural products 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229960001334 corticosteroids Drugs 0.000 claims description 4
- 229960002311 dithranol Drugs 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 229960002518 gentamicin Drugs 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000490 permethrin Drugs 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011269 tar Substances 0.000 claims description 4
- 210000003371 toe Anatomy 0.000 claims description 4
- 230000037317 transdermal delivery Effects 0.000 claims description 4
- 229960005294 triamcinolone Drugs 0.000 claims description 4
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- 229920000181 Ethylene propylene rubber Polymers 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 210000002683 foot Anatomy 0.000 claims description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002751 imiquimod Drugs 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920001748 polybutylene Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920000098 polyolefin Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 239000012790 adhesive layer Substances 0.000 claims description 2
- 210000003423 ankle Anatomy 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 210000000617 arm Anatomy 0.000 claims description 2
- 210000001513 elbow Anatomy 0.000 claims description 2
- 210000003811 finger Anatomy 0.000 claims description 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000000689 upper leg Anatomy 0.000 claims description 2
- 210000000707 wrist Anatomy 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 125000000017 cortisol group Chemical group 0.000 claims 1
- 208000026721 nail disease Diseases 0.000 abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 208000017520 skin disease Diseases 0.000 abstract description 2
- 210000000282 nail Anatomy 0.000 description 60
- 210000003491 skin Anatomy 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000004681 Psoriasis Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000000260 Warts Diseases 0.000 description 8
- 201000010153 skin papilloma Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 210000004904 fingernail bed Anatomy 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004905 finger nail Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 230000001185 psoriatic effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 208000006187 Onycholysis Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004906 toe nail Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000002506 Darier Disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010018381 Glomus tumour Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000002078 Ingrown Nails Diseases 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010028698 Nail dystrophy Diseases 0.000 description 2
- 206010061304 Nail infection Diseases 0.000 description 2
- 206010028703 Nail psoriasis Diseases 0.000 description 2
- 206010048886 Onychoclasis Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 206010037649 Pyogenic granuloma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041663 Splinter haemorrhages Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 201000004607 keratosis follicularis Diseases 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 201000010192 nonsyndromic congenital nail disorder 1 Diseases 0.000 description 2
- 201000008743 palmoplantar keratosis Diseases 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 2
- 229960001896 pramocaine Drugs 0.000 description 2
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- PPOCFSJSVCAFQQ-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1CC2(C)C(=O)CC1C2(C)C.C1CC2(C)C(=O)CC1C2(C)C PPOCFSJSVCAFQQ-UHFFFAOYSA-N 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010022013 Ingrowing nail Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- 208000035450 Malformed Nails Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010058455 Nail pigmentation Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010030336 Onychogryphosis Diseases 0.000 description 1
- 206010049274 Onychomadesis Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040868 Skin hypopigmentation Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940008309 acetone / ethanol Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- AJXBTRZGLDTSST-UHFFFAOYSA-N amino 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)ON AJXBTRZGLDTSST-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910001567 cementite Inorganic materials 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000005620 dermis tumor Diseases 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000009356 dyskeratosis congenita Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- CBJHPWGNQLOEPT-UHFFFAOYSA-N ethenyl acetate Chemical compound CC(=O)OC=C.CC(=O)OC=C CBJHPWGNQLOEPT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 208000011886 nail tumor Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 208000011856 onychomatricoma Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 208000003619 porokeratosis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ZJHHPAUQMCHPRB-UHFFFAOYSA-N urea urea Chemical compound NC(N)=O.NC(N)=O ZJHHPAUQMCHPRB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002025 wood fiber Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26043001P | 2001-01-09 | 2001-01-09 | |
| PCT/US2002/000282 WO2002055023A2 (en) | 2001-01-09 | 2002-01-07 | Therapeutic film forming composition and treatment system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004520337A true JP2004520337A (ja) | 2004-07-08 |
Family
ID=22989129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555760A Pending JP2004520337A (ja) | 2001-01-09 | 2002-01-07 | フィルム形成治療化合物および治療システム |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1357873A4 (zh) |
| JP (1) | JP2004520337A (zh) |
| KR (1) | KR20030072592A (zh) |
| CN (1) | CN1281287C (zh) |
| AU (1) | AU2002248308B2 (zh) |
| BR (1) | BR0206307A (zh) |
| CA (1) | CA2431236A1 (zh) |
| HU (1) | HUP0501023A3 (zh) |
| IL (1) | IL156458A0 (zh) |
| NO (1) | NO20033123L (zh) |
| NZ (1) | NZ526806A (zh) |
| PL (1) | PL362920A1 (zh) |
| WO (1) | WO2002055023A2 (zh) |
| ZA (1) | ZA200305125B (zh) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007015973A (ja) * | 2005-07-07 | 2007-01-25 | Nippon Kenko Kagaku Kenkyu Center:Kk | 浴用フィルム製剤 |
| JP2008105979A (ja) * | 2006-10-24 | 2008-05-08 | Nippon Kenko Kagaku Kenkyu Center:Kk | フィルムガード製剤 |
| JP2009519940A (ja) * | 2005-12-14 | 2009-05-21 | ザーズ， インコーポレイテッド | 皮膚科学的状態を処置するための組成物および方法 |
| JP2010518130A (ja) * | 2007-02-15 | 2010-05-27 | ポリケム・エスエイ | 皮膚に薬物を放出するための皮膚膜形成液体製剤 |
| JP2012506372A (ja) * | 2008-10-21 | 2012-03-15 | ピエール、ファブレ、デルモ‐コスメティーク | 爪乾癬治療のための尿素ベースフィルム形成溶液 |
| JP2017503818A (ja) * | 2014-01-20 | 2017-02-02 | メリアル インコーポレイテッド | 局所送達製剤 |
| US9675562B2 (en) | 2004-06-07 | 2017-06-13 | Crescita Therapeutics Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| US8741332B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
| US8771656B2 (en) * | 2011-12-14 | 2014-07-08 | Avon Products, Inc | Long-lasting easy wash-off cosmetic compositions |
| CN104661655A (zh) * | 2012-07-23 | 2015-05-27 | 陶氏环球技术有限责任公司 | 用于硬质胶囊外壳的膜组合物 |
| PL2705847T3 (pl) * | 2012-09-05 | 2015-02-27 | Psoriasis Creams Sweden Ab | Kompozycja do leczenia łuszczycy |
| CN104771781A (zh) * | 2014-08-20 | 2015-07-15 | 江阴市柏御天谷生物医药有限公司 | 液体创面保护膜及其制备方法 |
| CN105999393A (zh) * | 2016-07-15 | 2016-10-12 | 蓝佳堂生物医药（福建）有限公司 | 一种液体创可贴及其制备方法 |
| CN107320766A (zh) * | 2016-12-08 | 2017-11-07 | 沈阳圣劳伦斯医疗器械有限公司 | 一种用于皮肤浅表创面保护的组合物 |
| CN108785739A (zh) * | 2018-08-13 | 2018-11-13 | 中国人民解放军南京军区福州总医院 | 一种多功能液体创可贴及其制备方法 |
| CN110859989B (zh) * | 2019-10-25 | 2021-06-22 | 天津冠勤医药科技有限公司 | 一种液体创可贴及其制备方法 |
| CN111166932B (zh) * | 2020-02-29 | 2021-01-26 | 海南妙音春制药有限公司 | 一种液体伤口喷剂敷料及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612305A1 (de) * | 1986-04-11 | 1987-10-22 | Roehm Pharma Gmbh | Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere |
| DE4212105A1 (de) * | 1992-04-10 | 1993-10-14 | Roehm Pharma Gmbh | Nagellack zur Behandlung von Onychomykosen |
| US5534021A (en) * | 1994-09-01 | 1996-07-09 | Dvoretzky; Israel | Heating pad for providing heat therapy |
| JP4547046B2 (ja) * | 1995-06-29 | 2010-09-22 | ワイス・エルエルシー | ヒートセル |
| RO118174B1 (ro) * | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Lac de unghii şi utilizarea acestuia |
-
2002
- 2002-01-07 PL PL02362920A patent/PL362920A1/xx unknown
- 2002-01-07 CN CNB028035100A patent/CN1281287C/zh not_active Expired - Fee Related
- 2002-01-07 EP EP02717290A patent/EP1357873A4/en not_active Withdrawn
- 2002-01-07 NZ NZ526806A patent/NZ526806A/xx unknown
- 2002-01-07 AU AU2002248308A patent/AU2002248308B2/en not_active Ceased
- 2002-01-07 KR KR10-2003-7009178A patent/KR20030072592A/ko not_active Application Discontinuation
- 2002-01-07 IL IL15645802A patent/IL156458A0/xx not_active IP Right Cessation
- 2002-01-07 HU HU0501023A patent/HUP0501023A3/hu unknown
- 2002-01-07 WO PCT/US2002/000282 patent/WO2002055023A2/en active Application Filing
- 2002-01-07 BR BR0206307-7A patent/BR0206307A/pt not_active IP Right Cessation
- 2002-01-07 CA CA002431236A patent/CA2431236A1/en not_active Abandoned
- 2002-01-07 JP JP2002555760A patent/JP2004520337A/ja active Pending
-
2003
- 2003-07-01 ZA ZA200305125A patent/ZA200305125B/en unknown
- 2003-07-08 NO NO20033123A patent/NO20033123L/no not_active Application Discontinuation
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675562B2 (en) | 2004-06-07 | 2017-06-13 | Crescita Therapeutics Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
| JP2007015973A (ja) * | 2005-07-07 | 2007-01-25 | Nippon Kenko Kagaku Kenkyu Center:Kk | 浴用フィルム製剤 |
| JP2009519940A (ja) * | 2005-12-14 | 2009-05-21 | ザーズ， インコーポレイテッド | 皮膚科学的状態を処置するための組成物および方法 |
| JP2008105979A (ja) * | 2006-10-24 | 2008-05-08 | Nippon Kenko Kagaku Kenkyu Center:Kk | フィルムガード製剤 |
| JP2010518130A (ja) * | 2007-02-15 | 2010-05-27 | ポリケム・エスエイ | 皮膚に薬物を放出するための皮膚膜形成液体製剤 |
| JP2012506372A (ja) * | 2008-10-21 | 2012-03-15 | ピエール、ファブレ、デルモ‐コスメティーク | 爪乾癬治療のための尿素ベースフィルム形成溶液 |
| JP2017503818A (ja) * | 2014-01-20 | 2017-02-02 | メリアル インコーポレイテッド | 局所送達製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1357873A2 (en) | 2003-11-05 |
| CN1281287C (zh) | 2006-10-25 |
| BR0206307A (pt) | 2004-07-20 |
| KR20030072592A (ko) | 2003-09-15 |
| CA2431236A1 (en) | 2002-07-18 |
| NO20033123L (no) | 2003-09-03 |
| IL156458A0 (en) | 2004-01-04 |
| WO2002055023A3 (en) | 2002-11-07 |
| ZA200305125B (en) | 2004-10-01 |
| AU2002248308B2 (en) | 2006-12-07 |
| WO2002055023A2 (en) | 2002-07-18 |
| NO20033123D0 (no) | 2003-07-08 |
| CN1514706A (zh) | 2004-07-21 |
| NZ526806A (en) | 2006-03-31 |
| HUP0501023A2 (en) | 2007-02-28 |
| HUP0501023A3 (en) | 2008-04-28 |
| EP1357873A4 (en) | 2009-09-09 |
| PL362920A1 (en) | 2004-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520337A (ja) | フィルム形成治療化合物および治療システム | |
| US20080102108A1 (en) | Therapeutic film forming composition and treatment system therefor | |
| SI20360A (sl) | Sredstva in metode za zdravljenje motenj v zvezi z neuravnovešenostjo ter hiperaktivnih motenj v zvezi z neuravnovešenostjo s pomočjo metilfenidata | |
| ES2733812T3 (es) | Polímeros acrílicos que contienen silicona para composiciones de administración transdérmica de fármacos | |
| AU586770B2 (en) | Transdermal verapamil delivery device | |
| AU2002248308A1 (en) | Therapeutic film forming composition and treatment system | |
| US20050208115A1 (en) | Multi-purpose combined drug delivery and heat therapy treatment system | |
| JPH06503576A (ja) | 皮膚浸透増強剤としてソルビタンエステルを用いた経皮的に薬物を投与するための方法およびシステム | |
| JPS59155268A (ja) | 薬剤注入装置 | |
| CN104936582B (zh) | 用于激素和其他药剂的经皮传送的组合物和方法 | |
| MX2007003995A (es) | Formulaciones de organo-gel para aplicaciones terapeuticas. | |
| JP2002531488A5 (zh) | ||
| CN108078961A (zh) | 一种洛索洛芬钠贴剂 | |
| WO2000001384A1 (fr) | Preparation a base de ketotifene destinee a etre absorbee par voie percutanee | |
| JPH09315964A (ja) | 肩こり・五十肩治療用貼付剤 | |
| CN114209974B (zh) | 一种石墨烯药物载体贴 | |
| US20100158990A1 (en) | Transdermal method and patch for corticosteroid administration | |
| JP5027373B2 (ja) | エストラジオール含有貼付剤 | |
| Munoz | OESCLIM®: an advanced delivery system for HRT | |
| AU2016362979A1 (en) | Systems and methods for transdermal drug delivery | |
| JPH05367B2 (zh) | ||
| EP2520289B1 (en) | Norethisterone-containing patch | |
| US20160008274A1 (en) | Treatment of nail disorders | |
| JP4919573B2 (ja) | ノルエチステロン含有外用貼付剤 | |
| KR960011233B1 (ko) | 0차 흡수속도를 갖는 지속성 경피투여 제형 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080819 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |